Objective-Peroxisome proliferator-activated receptor-␥ (PPAR␥) ligands attenuate angiotensin II (Ang II)-induced atherosclerosis through interactions with vascular smooth muscle cell (VSMC)-specific PPAR␥ in hypercholesterolemic mice. Therefore, the purpose of this study was to determine the mechanism of Ang II-mediated intracellular regulation of PPAR␥ in VSMCs. Methods and Results-Incubation of cultured mouse aortic VSMCs with Ang II for 24 hours reduced abundance of PPAR␥ protein, mRNA, and transcriptional activity (PϽ0.001). This effect was attenuated by an angiotensin type 1 receptor antagonist, losartan. Ang II-induced PPAR␥ reduction was dependent on stimulation of transforming growth factor (TGF)-␤1 as demonstrated using either a neutralizing antibody or small interfering RNA (siRNA). Ang II-induced TGF-␤1 secretion was dependent on epidermal growth factor receptor kinase activation through reactive oxygen species production. Inhibition of p38 mitogen-activated protein kinase by SB203580 or siRNA inhibited both Ang II-and TGF-␤1-induced PPAR␥ reduction. Blockade of TGF-␤1 decreased p38 phosphorylation induced by Ang II. siRNA-mediated inhibition of histone deacetylase 3 attenuated p38-mediated reductions in PPAR␥ abundance. Conclusion-These findings suggest that Ang II decreases PPAR␥ abundance in cultured VSMCs via an angiotensin type 1 receptor-dependent secretion of TGF-␤1 via phosphorylation of p38 mitogen-activated protein kinase and histone deacetylase 3. (Arterioscler Thromb Vasc Biol. 2012;32:397-405.)
P eroxisome proliferator-activated receptor-␥ (PPAR␥) is a transcription factor belonging to the nuclear hormone receptor superfamily. 1 PPAR␥ is predominantly expressed in adipose tissue and has been characterized as an important regulator of adipocyte differentiation and glucose homeostasis. 2 PPAR␥ is also expressed in macrophages, endothelial cells, and vascular smooth muscle cells (VSMCs), where it regulates gene expression of key proteins involved in vascular inflammation and proliferation. 3 PPAR␥ ligands, namely the thiazolidinedione compounds, reduce hypercholesterolemia-induced and angiotensin II (Ang II)-enhanced atherosclerosis in apolipoprotein E-deficient 4 and low-density lipoprotein receptor-deficient 5, 6 mice. We showed recently that a thiazolidinedione compound, pioglitazone, attenuated Ang II-induced atherosclerosis through interactions with PPAR␥ expressed in VSMCs. 6 Conversely, PPAR␥ ligands also modulate Ang II signaling in VSMCs both at the receptor level and downstream of angiotensin type 1 (AT 1 ) receptors. 7, 8 Ang II has been demonstrated to reduce PPAR␥ transcriptional activity through the activation of breakpoint cluster region (BCR) kinase in VSMCs. 9 However, the effect of Ang II on PPAR␥ gene expression and the mechanisms by which Ang II interacts with PPAR␥ in VSMCs remain poorly understood.
Transforming growth factor-␤ (TGF-␤) molecules are a family of cytokines with multiple effects on growth and development. 10 Ang II induces autocrine production of TGF-␤1 in VSMCs that mediates its mitogenic effects. 11 The primary downstream effectors of TGF-␤ signal transduction are Smad signaling proteins. In addition to Smad proteins, mitogen-activated protein kinases (MAPKs) have also been invoked as downstream effectors of TGF-␤ signaling. 12, 13 In VSMCs, PPAR␥ and TGF-␤1 signal transduction pathways have mutual regulatory mechanisms. PPAR␥ activation was initially shown to inhibit TGF-␤1-induced connective tissue growth factor expression in human aortic VSMCs. 14 Subsequently , it was demonstrated that TGF-␤1 had a biphasic effect by exerting a rapid induction fol-lowed by a strong repression on PPAR␥ gene transcription in aortic VSMCs. 15 Collectively, in the literature, it is known that (1) Ang II reduces PPAR␥ transcriptional activity in VSMCs through BCR kinase activation, (2) TGF-␤1 represses PPAR␥ transcription in VSMCs, and (3) Ang II activates p38 MAPK in VSMCs via the activation of epidermal growth factor receptor (EGFR) kinase and reactive oxygen species (ROS) production. In this study, we provide novel evidence that (1) Ang II reduces PPAR␥ protein and mRNA in aortic VSMCs associated with reduced transcriptional activity via AT 1 receptors. In addition, the present study showed new evidence that (2) Ang II activates p38 MAPK via EGFR kinasemediated induction of TGF-␤1 and causes a reduction in expression of PPAR␥ protein.
(3) Furthermore, Ang II-activated p38 MAPK decreases PPAR␥ protein in a histone deacetylase 3 (HDAC3)-dependent manner. (4) Ang II-TGF-␤1-p38 MAPK-mediated reduction of PPAR␥ in VSMCs is independent of Ang II-induced Bcr kinase activation. (5) Furthermore, we showed that TGF-␤1 mediates its effect on PPAR␥ independent of the Smad-2 pathway.
Materials and Methods
A detailed description of all methods is presented in the supplemental materials, available online at http://atvb.ahajournals.org.
Isolation and Culture of VSMCs
Mouse aortas were sectioned into thoracic, suprarenal, and infrarenal regions, and VSMCs were isolated as described previously. 16 All procedures were approved by the University of Kentucky Institutional Animal Care and Use Committee.
Cell Culture
VSMCs were incubated with either saline or Ang II (1 mol/L) for 24 hours to measure PPAR␥ expression and transcriptional activity or for 0 to 60 minutes to measure MAPK activity and TGF-␤1 expression. Pharmacological inhibitors were added 30 minutes before addition of Ang II. Incubation with recombinant TGF-␤1 (10 ng/mL) or active p38 (100 nmol/L) for 30 minutes or 24 hours was used to measure MAPK activity or PPAR␥ mRNA abundance.
Western Blot Analyses
Total cell lysates were used for Western blot analyses.
Real-Time Polymerase Chain Reaction
Real-time polymerase chain reactions were performed using an iCycler (Bio-Rad) as described previously. 17
Transient Transfection Assays
PPAR␥1 promoter luciferase activities were analyzed using transient transfection assays as described previously. 18
RNA Silencing Experiments
Small interfering RNA (siRNA) experiments were performed using the On-Target Plus SMARTpool technology.
Statistical Analyses
All data are reported as meansϮSEMs. Statistic analyses were performed as appropriate for number of groups and the parametric or nonparametric nature of the data.
Results

Ang II Decreased Expression of PPAR␥ in Aortic VSMCs Via Interaction With AT 1 Receptors
To investigate whether Ang II regulates expression of PPAR␥, VSMCs isolated from thoracic, suprarenal, and infrarenal aortic regions were incubated with Ang II (1 mol/L) for 24 hours. Ang II decreased PPAR␥ protein abundance in VSMCs from all regions ( Figure 1A ). All subsequent experiments were conducted with cells obtained from the suprarenal region. To examine the role of AT 1 receptors in Ang II-induced PPAR␥ regulation, VSMCs were preincubated with losartan for 30 minutes followed by Ang II incubation for 24 hours. Blockade of AT 1 receptors with losartan prevented Ang II-induced decreases in PPAR␥ protein abundance (PϽ0.001, Figure 1B ). In addition, activation of PPAR␥ by the ligand rosiglitazone (10 mol/L) completely inhibited Ang II-induced reduction in PPAR␥, implying that Ang II mediated its effect on PPAR␥ via inhibition of PPAR␥ transcriptional activity ( Figure 1C ).
Ang II Decreased PPAR␥ by a Transcriptional Mechanism Via AT 1 Receptors
To assess whether Ang II-induced reduction in PPAR␥ abundance occurred by a transcriptional mechanism, VSMCs were incubated with either vehicle or Ang II for 24 hours. Ang II reduced PPAR␥ mRNA abundance in aortic VSMCs via AT 1 receptors (PϽ0.001, Figure 1D ). To assess whether Ang II-induced reduction in PPAR␥ expression was associated with changes in transcriptional activity, VSMCs were transiently transfected with a PPAR␥ promoter construct and then incubated with Ang II for 24 hours. As shown in Figure  1E , Ang II inhibited PPAR␥ transcriptional activity via AT 1 receptors.
Involvement of TGF-␤1 Signaling in PPAR␥ Regulation
TGF-␤1 regulates PPAR␥ expression in several cell types, including VSMCs. 15 Ang II also activates TGF-␤1 in VSMCs. 19 To study whether activation of TGF-␤1 regulates PPAR␥, VSMCs were preincubated with a TGF-␤1neutralizing antibody for 30 minutes, followed by incubation with Ang II for 24 hours. Neutralization of TGF-␤1 activity completely reversed Ang II-induced decreases in PPAR␥ protein abundance ( Figure 2A ). In addition, Ang II stimulation, after blocking TGF-␤1 activity, increased abundance of PPAR␥ protein (PϽ0.001, Figure 2A ).
Involvement of p38 MAPK in Regulation of PPAR␥ Expression
Members of the MAPK superfamily are known to regulate PPAR␥ expression in VSMCs. 20, 21 To study whether MAPK activation (p38, extracellular signal-regulated kinases [ERK] and c-Jun N-terminal kinases [JNK]) plays a role in Ang II-induced PPAR␥ regulation, VSMCs were preincubated with SP600125 (JNK inhibitor), SB203580 (p38 inhibitor), or PD98059 (ERK inhibitor) for 30 minutes, followed by incubation with Ang II for 24 hours. Pretreatment with SB203580, a p38 inhibitor, completely prevented the reduction of PPAR␥ protein (PϽ0.001, Figure 2B ), whereas incubation with either SP600125 or PD98059 had no effect on Ang II-induced decreases of PPAR␥ protein (Supplemental Figure I ). In addition, Ang II incubation after p38 MAPK inhibition significantly increased PPAR␥ protein abundance (PϽ0.001, Figure 2B ), similar to the effect of neutralization of TGF-␤1 activity (Figure 2A ). To examine the specificity of SB203580 compound on its target p38 MAPK, VSMCs were preincubated with SB203580 for 30 minutes followed by incubation with Ang II for 30 minutes. SB203580 inhibited p38 phosphorylation induced by Ang II (PϽ0.001, Figure 2C ).
The role of TGF-␤1 and p38 on Ang II-induced PPAR␥ reductions was further confirmed by using siRNA-mediated reductions of either TGF-␤1 or p38 in VSMCs. Silencing of TGF-␤1 (Supplemental Figure IIA Figure IIIA ), suggesting that Ang II-induced effects were mediated by TGF-␤1 and p38. In addition, Ang II incubation after siRNAinduced reductions of either TGF-␤1 or p38 significantly increased PPAR␥ protein abundance (PϽ0.001; Supplemental Figure IIIA ), similar to neutralization of TGF-␤1 activity (Figure 2A ). To further understand whether Ang II mediates superinduction of PPAR␥ through ERK or JNK MAPK, VSMCs were preincubated with either PD98059 or SP600125 in combination with a TGF-␤1 neutralizing antibody for 30 minutes, followed by incubation with Ang II. PD98059 or SP600125 did not influence PPAR␥ superinduction (Supplemental Figure IIIB ), suggesting that neither ERK nor JNK is involved in Ang II-induced superinduction of PPAR␥ after TGF-␤1 neutralization.
TGF-␤1 Downregulated PPAR␥ Via Activation of p38 MAPK
Inhibition of either TGF-␤1 or p38 MAPK prevented the Ang II-induced reduction in PPAR␥ protein abundance in VSMCs. To examine whether TGF-␤1 activation mediated its effect via p38 MAPK, VSMCs were preincubated with SB203580 for 30 minutes and then incubated with recombinant TGF-␤1 for 24 hours. TGF-␤1 incubation significantly decreased PPAR␥ protein via p38 MAPK (PϽ0.001; Figure  2D ). The involvement of p38 was further confirmed with siRNA-mediated knockdown of p38 in VSMCs. Silencing of p38 completely prevented the reduction of PPAR␥ protein (PϽ0.001; Supplemental Figure IV) , which further confirmed that the effects of TGF-␤1 are mediated by p38.
Kinetics of Ang II Activation of p38 MAPK Via TGF-␤1
We determined the kinetics of Ang II activation of p38 and TGF-␤1 in VSMCs by incubating cells with Ang II for 0 to 60 minutes. Western blot analyses demonstrated that Ang II incubation led to p38 phosphorylation that was maximal after 20 minutes (PϽ0.05; Figure 3A ) and returned to basal level Angiotensin II (Ang II) decreased peroxisome proliferator-activated receptor-␥ (PPAR␥) protein, mRNA abundance, and transcriptional activity. A, Thoracic, suprarenal, and infrarenal aorta-derived vascular smooth muscle cells (VSMCs) were incubated with either vehicle (saline) or Ang II (1 mol/L) for 24 hours and lysed, and proteins were resolved by SDS-PAGE. Western analyses were performed to detect PPAR␥ protein (nϭ3). B, VSMCs were incubated with vehicle (saline), Ang II (1 mol/L), or Ang IIϩlosartan (10 mol/L) for 24 hours. Total cell lysates were analyzed by Western blotting using antibodies to PPAR␥ (nϭ5). C, VSMCs were preincubated with either vehicle (dimethyl sulfoxide) or rosiglitazone (10 mol/L) for 24 hours followed by incubation with either saline or Ang II (1 mol/L) for 24 hours. Total cell lysates were analyzed by Western blotting using antibodies to PPAR␥ (nϭ3). Abundance of ␤-actin was used as an internal control. D, VSMCs were incubated with vehicle (saline), Ang II (1 mol/L), or Ang IIϩlosartan (10 mol/L) for 24 hours. Total RNA was extracted from these cells and then subjected to quantitative reverse transcription-polymerase chain reaction analyses. 18S was used as an internal control (nϭ4). E, VSMCs were transiently transfected with PPAR␥ promoter luciferase reporter construct along with plasmid encoding Renilla luciferase. After transfection, cells were serum deprived and incubated with either vehicle (saline) or Ang II for 24 hours. Transfection efficiency was adjusted by normalizing firefly luciferase activities to Renilla luciferase activities (nϭ4). Results are represented as meansϮSEMs. Data were analyzed by 1-way ANOVA with a Holm-Sidak multiple comparison post hoc test.
after 45 minutes (data not shown). In addition, Ang II incubation also increased TGF-␤1 protein expression significantly within 10 minutes of incubation (PϽ0.05; Figure 3B ).
TGF-␤1 has also been shown to mediate its downstream effect via MAPK activation. 13 To examine whether TGF-␤1 activated p38 MAPK in VSMCs, cells were incubated with recombinant TGF-␤1 for selected time intervals (0 -60 minutes). Western blot analyses demonstrated increased p38 phosphorylation after 10 minutes incubation with TGF-␤1 (PϽ0.05; Figure 3C ). VSMCs were preincubated with a TGF-␤1 neutralizing antibody for 30 minutes, followed by incubation with Ang II for 30 minutes, to determine whether Ang II induced MAPK activation through TGF-␤1 stimulation. Inhibition of TGF-␤1 decreased the p38 phosphorylation induced by Ang II (PϽ0.05, Figure 3D ) but had no effect on phosphorylation of JNK and ERK (Supplemental Figure V ).
EGFR and ROS Inhibition Suppressed Ang II But Not TGF-␤1-Induced p38 MAPK Activation
Ang II-induced transactivation of EGFRs with ROS production has been shown to mediate p38 activation in VSMCs. 22 To understand whether EGFR and ROS production are involved in Ang II-induced p38 MAPK activation (either upstream or downstream of TGF-␤1), VSMCs were preincubated with the EGFR kinase inhibitor AG1478 or an antioxidant, N-acetyl L-cysteine (NAC), for 30 minutes followed by incubation with either Ang II or recombinant TGF-␤1 for 20 or 10 minutes, respectively. Inhibition of EGFR and ROS significantly blunted Ang II-induced p38 activation (vehicle: 1.4Ϯ0.2 AU; Ang II: 173.7Ϯ45.0 AU; Ang IIϩAG1478: 0.4Ϯ0.003 AU; Ang IIϩNAC: 1.6Ϯ0.4 AU; PϽ0.05 versus Ang II; Figure 4A ) but had no effect on TGF-␤1-induced p38 activation (vehicle: 1.0Ϯ0.7; TGF-␤1: 133.0Ϯ32.8; TGF-␤1ϩAG1478: 122.0Ϯ31.1; TGF-␤1ϩNAC: 125.9Ϯ9.9; PϽ0.05 versus vehicle; Figure 4B ). In addition, EGFR and ROS inhibition also significantly decreased Ang II-induced TGF-␤1 protein in VSMCs (vehicle: 1.0Ϯ0.05; Ang II: 1.8Ϯ0.21; Ang IIϩAG1478: 1.08Ϯ0.11; Ang IIϩNAC: 1.02Ϯ0.06; PϽ0.05 versus Ang II; Figure 4C ), indicating that EGFR and ROS are acting upstream of TGF-␤1 and involved in Ang II-induced TGF-␤1 production.
p38 Downregulated PPAR␥ Via HDAC3
To further understand the downstream signaling mechanism of p38-mediated reduction in PPAR␥, first we examined the effects of recombinant active p38 protein on PPAR␥ protein abundance and transcriptional activity in VSMCs. VSMCs transiently transfected with a PPAR␥ promoter construct were incubated with either vehicle or recombinant active p38 for 24 hours. For protein expression studies, VSMCs were incubated with either vehicle or recombinant active p38 for 24 hours. Active p38 significantly inhibited PPAR␥ transcriptional activity and protein expression in VSMCs (PϽ0.05; Figure 4D and 4F).
Members of the HDAC family, especially HDAC3, have been shown to repress PPAR␥ in complex with retinoblastoma protein. 23 Because HDACs have also been shown to mediate Ang II-induced VSMC hypertrophy, 24 we sought to determine the involvement of HDAC in Ang II-p38 -mediated reduction in PPAR␥ in VSMCs. VSMCs were preincubated with a HDAC inhibitor, trichostatin A, for 30 minutes followed by incubation with either Ang II or recombinant active p38 protein for 24 hours. Trichostatin A-induced HDAC inhibition prevented both Ang II-and p38-induced decreases in PPAR␥ protein abundance (PϽ0.05; Figure 4E and 4F). This is consistent with an involvement of HDACs downstream of p38 in Ang II-mediated PPAR␥ reduction. In addition, Western analyses showed that incubation with either Ang II or active p38 led to increased HDAC3 protein in VSMCs (vehicle: 0.89Ϯ0.06; Ang II: 1.86Ϯ0.2; active p38: 1.77Ϯ0.02; PϽ0.05 versus vehicle; Supplemental Figure VI ). Next, we examined whether siRNA-induced reduction of HDAC3 would mimic the effects of HDAC inhibition on Ang II-p38 -induced reductions in PPAR␥. VSMCs were transfected with HDAC3 siRNA for 48 hours followed by incubation with either Ang II or active p38 for 24 hours. HDAC3 silencing (Supplemental Figure VII) completely prevented Ang II-p38 -induced reduction of PPAR␥ protein (PϽ0.05; Figure 4G and 4H ), suggesting the involvement of HDAC3 (downstream of p38) in Ang II-mediated PPAR␥ reduction in VSMCs.
BCR Kinase Differentially Regulated Ang II-and TGF-␤1-Induced PPAR␥ Reduction
Activation of BCR kinase by Ang II has been shown to inhibit PPAR␥ transcriptional activity and induces nuclear factor-B (NF-B) activation in VSMCs. 9 To determine whether BCR kinase and activated NF-B were involved in the Ang II-TGF-␤1-p38 MAPKs pathway to reduce PPAR␥ in VSMCs, first we examined BCR kinase activation by either Ang II or TGF-␤1. VSMCs were incubated with either Ang II or TGF-␤1 for 0 to 10 minutes. Western blot analyses of cellular extracts using phospho-BCR kinase antibodies demonstrated that Ang II incubation led to BCR kinase phosphorylation that was maximal at 5 minutes ( Figure 5A ) and returned to basal levels after 10 minutes. In contrast, TGF-␤1 incubation has no effect on BCR kinase activation ( Figure 5B ). Next, we examined whether BCR kinase silencing in VSMCs would inhibit Ang II-TGF-␤1-induced PPAR␥ reduction. VSMCs were transfected with BCR kinase siRNA for 48 hours followed by incubation with either Ang II or TGF-␤1 for 24 hours. BCR kinase silencing ( Figure 5C ) prevented Ang IIinduced reduction of PPAR␥ protein (PϽ0.001; Figure  5D ) but did not influence PPAR␥ protein reduction induced by TGF-␤1 ( Figure 5E ). In addition, BCR kinase silencing had no effect on Ang II-induced TGF-␤1 protein expression ( Figure 5F ). Neutralization of TGF-␤1 did not influence Ang II-induced NF-B activation in VSMCs (Supplemental Figure VIIIA) . Furthermore, inhibition of NF-B activation using 2 different inhibitors (SN50-cell permeable inhibitor peptide and NF-B activation inhibitor) had no effect on either Ang II-or TGF-␤1-induced reduction in PPAR␥ protein (Supplemental Figure VIIIB) . These results suggest that Ang II-induced BCR kinase and NF-B activation are not involved in TGF-␤1-p38 MAPK-mediated downregulation of PPAR␥.
Blockade of p38 MAPK Did Not Influence TGF-␤1-Induced Smad Phosphorylation
Smad signaling proteins are the primary downstream effectors of TGF-␤ signal transduction. To determine whether TGF-␤1-induced Smad activation is affected by p38 MAPK inhibition, VSMCs were preincubated with SB203580 for 30 minutes followed by incubation with recombinant TGF-␤1 for 24 hours. TGF-␤1 promoted phosphorylation of Smad-2 in the presence of a p38 MAPK inhibitor (Supplemental Figure IX) , indicative that this pathway was not involved in Ang II-induced reduction of PPAR␥.
Discussion
In the present study, we examined PPAR␥ regulation by Ang II in mouse aortic VSMCs. The findings of this study demonstrate that Ang II decreases expression of PPAR␥ via AT 1 receptors in VSMCs. Furthermore, this Ang II-induced A and B , Vascular smooth muscle cells (VSMCs) were preincubated with AG1478 (100 nmol/L) or N-acetyl L-cysteine (NAC) (10 mmol/L) for 30 minutes followed by incubation with either vehicle (saline) or Ang II (A)/recombinant transforming growth factor (TGF)-␤1 (B) for 20 and 10 minutes, respectively. Total cell lysates were analyzed by Western blot using antibodies to phospho-p38 or p38 (nϭ3). C, VSMCs were preincubated with AG1478 (100 nmol/L), or NAC (10 mmol/L) for 30 minutes followed by incubation with either vehicle (saline) or Ang II for 10 minutes. Total cell lysates were analyzed by Western blot using antibodies to TGF-␤1 (nϭ3). D, VSMCs were transiently transfected with a PPAR␥ promoter luciferase reporter construct along with plasmid encoding Renilla luciferase. After transfection, cells were serum deprived and stimulated with vehicle (saline) or recombinant active p38 (100 nmol/L) for 24 hours. Transfection efficiency was adjusted by normalizing firefly luciferase activities to Renilla luciferase activities (nϭ4). E and F, VSMCs were preincubated with trichostatin A (TSA) (1 mol/L) for 30 minutes followed by incubation with either vehicle (saline) or Ang II (E)/recombinant active p38 (F) for 24 hours. Total cell lysates were analyzed by Western blot using antibodies to PPAR␥ (nϭ4). G and H, VSMCs were either transfected with HDAC3 small interfering RNA (siRNA) for 48 hours or preincubated with TSA for 30 minutes followed by incubation with either vehicle (saline) or Ang II (G)/recombinant active p38 (H) for 24 hours. Total cell lysates were analyzed by Western blot using antibodies to PPAR␥ (nϭ4). ␤-Actin was used as an internal control. Results are represented as meansϮSEMs. Data were analyzed by 1-way ANOVA with a Holm-Sidak multiple comparison post hoc test. decrease in PPAR␥ occurs via TGF-␤1 and the p38 MAPK pathway. Ang II activated p38 via TGF-␤1 and decreased PPAR␥ through HDAC3 without involving Smad signaling.
In this study, blockade of AT 1 receptors with losartan inhibited Ang II-induced PPAR␥ reduction. AT 1 receptors mediate most responses to Ang II, and this receptor subtype is predominantly expressed in VSMCs. 25, 26 AT 1 receptor antagonists have been shown to activate PPAR␥ in various cell types, including adipocytes and VSMCs. 27, 28 Among the various AT 1 receptor antagonists, telmisartan has been shown to activate PPAR␥ within a 10 mol/L concentration, 28 whereas the losartan activates PPAR␥ only at a high concentration (100 mol/L). 29 In our study, losartan at 10 mol/L inhibited Ang II-induced PPAR␥ reduction, but it did not increase the abundance of PPAR␥ over the basal level, consistent with a PPAR␥-independent effect of the drug.
Antibody-induced neutralization of TGF-␤1 activity completely ablated Ang II-induced reductions in PPAR␥ abundance. Conversely, addition of exogenous recombinant TGF-␤1 to aortic VSMCs downregulated PPAR␥ protein expression. Previous studies have highlighted an interrelationship between Ang II and TGF-␤1 in selected cell types, including VSMCs. 19, 30 TGF-␤1 has also been shown to directly regulate PPAR␥ gene expression in VSMCs. 15 Furthermore, in our study, Ang II stimulation after neutralization of TGF-␤1 activity significantly increased abundance of PPAR␥ protein, which indicates that TGF-␤1 activity blockade synergizes with Ang II and upregulates PPAR␥.
Ang II is a powerful activator of the MAPK cascade system in both cultured VSMCs and in intact arteries. 31, 32 Activation of p38 MAPK contributes to Ang II-induced DNA synthesis 33 and migration in VSMCs. 34 Our results demonstrate that Western blotting using antibodies to phospho-BCR kinase or BCR kinase (nϭ3). C, VSMCs were transfected with either control or BCR kinase small interfering RNA (siRNA) for 48 hours, and total cell lysates were analyzed by Western blot using antibodies to BCR kinase (nϭ3). D and E, VSMCs were transfected with either control or BCR kinase siRNA for 48 hours, followed by incubation with either vehicle (dimethyl sulfoxide) or Ang II (D)/recombinant TGF-␤1 (E) for 24 hours. Total cell lysates were analyzed by Western blot using antibodies to PPAR␥ (nϭ3-4). F, VSMCs were transfected with either control or BCR kinase siRNA for 48 hours, followed by incubation with either vehicle (saline) or Ang II for 10 minutes. Total cell lysates were analyzed by Western blot using antibodies to TGF-␤1 (nϭ3). ␤-Actin was used as an internal control. Results are represented as meansϮSEMs. Data were analyzed by 1-way ANOVA with a Holm-Sidak multiple comparison post hoc test.
both Ang II and TGF-␤1 activate p38 MAPK to reduce PPAR␥ abundance in aortic VSMCs. Our data clearly indicate that Ang II activates p38 MAPK through TGF-␤1 signaling and thereby downregulates PPAR␥ in VSMCs. Consistent with these findings, a recent study showed that TGF-␤1-induced p38 MAPK-mediated induction of microR-NAs 143/145 in human coronary artery VSMCs. 35 Thus, although Ang II activates other MAPKs (eg, JNK and ERK1/2) 22 in VSMCs, p38 MAPK is the primary mediator of Ang II-induced PPAR␥ downregulation.
Ang II-induced EGFR kinase transactivation and ROS production has been shown to mediate p38 MAPK activation in VSMCs. 22 Consistent with this report, inhibition of EGFR kinase by AG1478 and scavenging of ROS using NAC abolished Ang II-induced p38 activation with no effect on TGF-␤1-induced p38 activation. These data suggest that EGFR kinase and ROS are act as upstream signals of TGF-␤1 in Ang II-induced p38 activation. Our data further showed that EGFR kinase and ROS are involved in Ang II-induced TGF-␤1 production confirming the involvement of TGF-␤1 in Ang II-mediated p38 activation in VSMCs.
HDAC3, a member of class I HDAC family, is well known to be a repressor of PPAR␥. In adipocytes, activation of HDAC3 represses PPAR␥ in complex with retinoblastoma protein and inhibits adipocyte differentiation. 23 In mice, liver-specific deletion of HDAC3 resulted in a significant upregulation of PPAR␥, mainly through nuclear hormone receptor-mediated regulation. 36 Our current study demonstrated that HDAC activation is involved in both Ang II-and p38-mediated reduction in PPAR␥. In support of this finding, recent studies have reported increased HDAC activity in mice infused with Ang II, 37 and pharmacological inhibition of HDACs prevented Ang II-induced abdominal aortic aneurysms 38 and cardiac hypertrophy in mice. 39 The observed reduction in PPAR␥ may be due to increased repression by HDAC3, induced by Ang II via the activation of TGF-␤1 and p38 MAPKs.
In a recent study, Ang II (200 nmol/L) inhibited PPAR␥ transcriptional activity, as defined by transcriptional activity using luciferase reporter constructs, via the activation of BCR kinase in rat and mouse VSMCs. 9 Our current study confirmed this report and also determined the effects of Ang II on PPAR␥ mRNA and protein abundance in addition to its effect on transcriptional activity. Activation of BCR kinase was shown to inhibit PPAR␥ transcriptional activity mainly by PPAR␥ phosphorylation without influencing the ERK1/2 and JNK activity. 9 Our data demonstrate that Ang II-induced TGF-␤1-p38 MAPK activation is independent of BCR kinase activation and further demonstrate that Ang II-p38 MAPK-mediated reduction in PPAR␥ abundance is HDAC3 dependent. These results suggest that Ang II-induced reduction in PPAR␥ via the activation of TGF-␤1-p38 MAPKs is produced by potentiating HDAC3-mediated repression of PPAR␥ in smooth muscle cells.
Smad proteins are the primary TGF-␤1 receptor substrates capable of signal transduction. 40 Although Smad-dependent responses represent 1 of the main signaling systems used by TGF-␤1 receptors, alternative signaling components, such as MAPKs, are able to mediate TGF-␤1-induced biological effects. An earlier report also suggest that in mouse VSMCs, p38 MAPK plays an essential and nonredundant role in TGF-␤1-dependent growth inhibition. 41 In addition, another recent study showed that p38 MAPK mediates TGF-␤1induced induction of microRNAs 143/145 in human coronary artery smooth muscle cells. 35 Consistent with these reports, our data also demonstrate that TGF-␤1 mediated its effect on PPAR␥ via p38 MAPK. In addition, our data also confirmed that TGF-␤1-induced Smad-2 phosphorylation was not influenced by p38 MAPK inhibition, which confirms that TGF-␤1-induced Smad-2 activation was not involved in Ang II-induced reduction of PPAR␥.
In summary, these data provide evidence that Ang II inhibits expression of PPAR␥ in VSMCs. This supports a novel link between Ang II and TGF-␤1 in the regulation of PPAR␥ induced by Ang II (Figure 6 ). In addition, the data also suggest that PPAR␥ protein may be involved in Ang II-induced structural changes of the vascular wall. Figure 6 . Proposed schematic representation of signaling pathways involved in the regulation of angiotensin II (Ang II)-induced decreases in peroxisome proliferator-activated receptor-␥ (PPAR␥) in aortic vascular smooth muscle cells (VSMCs). Ang II-induced decrease in PPAR␥ protein was regulated via angiotensin type 1 (AT 1 ) receptor activation of transforming growth factor (TGF)-␤1, leading to subsequent induction of p38 mitogen-activated protein kinase (MAPK)-mediated histone deacetylase 3 (HDAC3). EGFR indicates epidermal growth factor receptor.
